Srikripa Devarakonda
Stock Analyst at Truist Securities
(4.17)
# 1,428
Out of 4,496 analysts
33
Total ratings
62.5%
Success rate
12.07%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VSTM Verastem | Maintains: Buy | $34 → $18 | $3.32 | +442.17% | 6 | Jul 8, 2024 | |
| LLY Eli Lilly | Reiterates: Buy | $892 → $1,000 | $857.47 | +16.62% | 2 | Jun 25, 2024 | |
| KROS Keros Therapeutics | Maintains: Buy | $100 | $48.38 | +106.70% | 3 | Jun 18, 2024 | |
| CYTK Cytokinetics | Maintains: Buy | $86 → $70 | $56.41 | +24.09% | 4 | May 29, 2024 | |
| INCY Incyte | Reiterates: Buy | $84 → $83 | $65.87 | +26.01% | 7 | May 1, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Buy | $25 | $21.36 | +17.04% | 4 | Apr 17, 2024 | |
| SRRK Scholar Rock Holding | Reiterates: Buy | $20 | $8.71 | +129.62% | 3 | Apr 3, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $41 → $54 | $43.10 | +25.29% | 2 | Mar 1, 2024 | |
| AFMD Affimed | Maintains: Buy | $80 → $60 | $5.15 | +1,065.05% | 2 | Aug 11, 2023 |
Verastem
Jul 8, 2024
Maintains: Buy
Price Target: $34 → $18
Current: $3.32
Upside: +442.17%
Eli Lilly
Jun 25, 2024
Reiterates: Buy
Price Target: $892 → $1,000
Current: $857.47
Upside: +16.62%
Keros Therapeutics
Jun 18, 2024
Maintains: Buy
Price Target: $100
Current: $48.38
Upside: +106.70%
Cytokinetics
May 29, 2024
Maintains: Buy
Price Target: $86 → $70
Current: $56.41
Upside: +24.09%
Incyte
May 1, 2024
Reiterates: Buy
Price Target: $84 → $83
Current: $65.87
Upside: +26.01%
Edgewise Therapeutics
Apr 17, 2024
Maintains: Buy
Price Target: $25
Current: $21.36
Upside: +17.04%
Scholar Rock Holding
Apr 3, 2024
Reiterates: Buy
Price Target: $20
Current: $8.71
Upside: +129.62%
Kymera Therapeutics
Mar 1, 2024
Maintains: Buy
Price Target: $41 → $54
Current: $43.10
Upside: +25.29%
Affimed
Aug 11, 2023
Maintains: Buy
Price Target: $80 → $60
Current: $5.15
Upside: +1,065.05%